FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

CHMP Recommends Approval of Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Home
/
insight
/
details

Primary Mutations Fueling Cancer Progression

NextEdge Admin

07 Oct 2023

3 min 34 sec

Driver mutations in cancer refer to specific genetic alterations or mutations that directly contribute to the initiation and progression of a cancerous growth. These mutations play a fundamental role in promoting tumorigenesis and are responsible for conferring a selective growth advantage to the affected cells, leading to their clonal expansion.

Key characteristics of driver mutations include:

Clonal Enrichment: Driver mutations are found in a significant proportion of cancer cells within a tumor, leading to their dominance and clonal expansion.
Contribution to Tumorigenesis: These mutations directly impact critical cellular pathways or genes involved in cell proliferation, DNA repair, or other fundamental cellular functions, leading to uncontrolled cell growth and cancer development.
Selective Advantage: They confer a selective growth advantage, allowing cells carrying these mutations to outcompete neighboring cells, contributing to tumor growth and survival.
Targetability for Therapy: Some driver mutations can be targeted for therapeutic interventions, leading to the development of precision medicine approaches in cancer treatment. The identification of driver mutations has been significantly aided by the advancements in genomic technologies, such as Next-Generation Sequencing (NGS). NGS allows the comprehensive analysis of a tumor’s genetic landscape, identifying various mutations and alterations in cancer-related genes. Examples of driver mutations can include alterations in well-known oncogenes (genes that can promote cancer development) or tumor suppressor genes (genes that usually prevent the development of cancer). For instance:

EGFR mutations in lung cancer
KRAS mutations in various cancers
TP53 mutations, a tumor suppressor gene, found in multiple cancer types
BRAF mutations in melanoma and other cancers

Identification of driver mutations is crucial in cancer research and clinical practice as they help in:

Understanding the biological mechanisms driving cancer growth
Tailoring treatments, especially targeted therapies that aim to block specific mutations or pathways
Predicting prognosis and disease progression

It’s important to note that not all genetic alterations identified in a tumor are driver mutations; some may be passenger mutations—genetic changes that occur randomly and do not significantly contribute to cancer development. The distinction between driver and passenger mutations is crucial in understanding the underlying biology of cancer and in developing targeted therapies.